Objectives-This study was performed to determine the frequency, predictors, and outcomes of ultrasound (US) correlates for non-mass enhancement.
adjunctive role in the management of MRI findings. Practice guidelines have been published to evaluate lesions detected by MRI. 12, 13 Management options for a suspicious lesion on MRI include proceeding directly to MRI-guided biopsy or performing an MRI-directed US examination, also known as second-look US or targeted US. A targeted US evaluation is performed in an attempt to identify a correlate for US-guided biopsy. Compared to MRI-guided biopsy, US-guided biopsy is better tolerated, less expensive, and faster, and it allows greater access to lesions in certain locations. 1, 5, 14, 15 Ultrasoundguided biopsy is also more widely available than MRIguided biopsy. On the other hand, potential disadvantages also exist for performing MRI-directed US examinations rather than proceeding directly to MRI-guided biopsy. This step may result in a prolonged workup time, added expense, and inaccurate correlations. 15 In addition, patients may have false reassurance in the setting of negative US findings.
The likelihood of identifying a US correlate for an MRI-detected abnormality depends on the lesion type. Multiple studies have shown that non-mass enhancement is less likely than a mass or focus to have a correlate. 5, [7] [8] [9] 15, 16 The purpose of our study was to determine the outcomes of non-mass enhancement on breast MRI and to correlate MRI-directed US imaging and the frequency of malignancy in the setting of non-mass enhancement.
Materials and Methods

Patients
The Institutional Review Board approved this Health Insurance Portability and Accountability Act-compliant retrospective study. Informed consent was waived. From January 2005 to December 2011, 5837 consecutive breast MRI examinations were performed in 4868 women at our institution. The mean patient age was 48.3 years (range, 22-85 years). Clinical indications were as follows: high-risk screening (3910 of 5837 [67.0%]), staging in newly diagnosed breast cancer (1390 of 5837 [23.8%] ), and problem solving (537 of 5837 [9.2%] ).
Magnetic Resonance Imaging Acquisition Parameters
Examinations were performed with the patient prone in a 3-T system (Tim Trio; Siemens Medical Solutions, Malvern, PA) using a dedicated 7-element breast coil (Invivo Corporation, Gainesville, FL). A precontrast sagittal T2-weighted sequence (repetition time/echo time, 8990/107 milliseconds) preceded a sagittal fatsuppressed T1-weighted 3-dimensional volume-interpolated breath hold examination sequence (repetition time/ echo time, 4.01/1.52 milliseconds; resolution, 1.4 3 0.9 3 1.5 mm 3 ), which was performed before and 4 times after an injection of gadopentetate dimeglumine (Magnevist, 0.1 mM/kg body weight; Berlex Laboratories, Inc, Montville, NJ) at 2 mL/s, followed by a saline flush with a power injector (Spectris Solaris; Medrad, Warrendale, PA). Contrast-enhanced dynamic sequences were obtained at approximately 100 seconds, and the dynamic study duration was approximately 6 to 7 minutes.
Magnetic Resonance Imaging-Directed US Technique
Magnetic resonance images were originally interpreted by 1 of 14 breast-imaging radiologists in our practice, who determined final Breast Imaging Reporting and Data System (BI-RADS) 17 assessment and management recommendations. A recommendation for an MRIdirected US examination versus direct MRI-guided biopsy at our institution was made on the basis of the best clinical judgment of the interpreting radiologist, which was formed by personal experience, including perceived likelihood of a lesion being seen on US imaging. Recommended MRI-directed US examinations were performed by a breast sonographer on a different day and interpreted by any one of the breast imaging radiologists. In 2005, we used 7-12-MHz linear array transducers (HDI 5000; Philips Healthcare, Bothell, WA; or LOGIQ 700; GE Healthcare, Wauwatosa, WI). From 2006 to 2011, we used 14-MHz linear array transducers (Acuson Sequoia; Siemens Medical Solutions).
Ultrasound-Guided Tissue Sampling
If a correlate was seen, US-guided biopsy was performed the same day. Ultrasound-guided core biopsies were performed with 14-gauge (Bard Biopsy, Tempe, AZ) or 12-gauge (Celero; Hologic, Inc, Bedford, MA) needle devices. Ultrasound-guided fine-needle aspiration biopsies were performed with either 23-or 25-gauge needles with a minimum of 3 passes and an on-site pathologist to determine adequacy of the sample and the diagnosis. The radiologist who performed the biopsy elected the biopsy type and subsequently assessed imaging-pathologic concordance.
Magnetic Resonance Imaging-Guided Biopsy
If no US correlate was found, further management was based on the original MRI report. In most cases, MRI-guided biopsy was recommended and performed on a different day than the MRI-directed US examination. The MRI-guided biopsy was performed on a 3-T system (Tim Trio; Siemens Healthcare) using a 7-element breast coil (Invivo Corporation) and a grid-localizing system (Biopsy Breast Device; Invivo Corporation). Computer-aided evaluation processing software (DynaCad; Invivo Corporation) was used to target the lesion. An MRI-compatible coaxial 9-gauge vacuum-assisted biopsy system (ATEC system, Suros Surgical Systems; Hologic, Inc) was used. Ten to 12 core samples were obtained in all cases.
Image Review and Landmark Evaluation
Breast MRI reports were reviewed for cases of non-mass enhancement yielding a final BI-RADS assessment of 3, 4, or 5 by the original interpreting radiologist for which further workup was recommended with MRI-directed US or MRI-guided biopsy. Associated patient demographics, non-mass enhancement characteristics, type of biopsy if performed, elapsed time to biopsy and surgery, if applicable, and histopathologic results were noted. We also recorded whether the original MRI report described any discrete MRI finding that could be used to guide the US evaluation. Such findings were categorized as "landmarks." We hypothesized that a landmark could be used as supplementary information in addition to the standard localizers of clock position and distance from the nipple to guide US evaluations, thus increasing the chance of identifying a correlate. Landmark types were grouped as index cancer, postsurgical scar or seroma, biopsy site or clip, benign mass, or dilated duct. The distance between the landmark and the lesion was measured by a single radiologist.
Data Collection
Mammographic density, background parenchymal enhancement, size, and kinetic enhancement of the lesions were recorded from the electronic medical records. In addition, an individual retrospective review of the images of the 918 non-mass enhancement lesions was performed by 2 fellowship-trained breast-imaging radiologists (with 5 and 14 years of experience) who were blinded to the clinical indications and pathologic findings. The reviewers classified the lesion type in accordance with the BI-RADS fifth edition lexicon. 17 A total of 879 of 918 lesions (96%) originally described as non-mass enhancement were also classified as non-mass enhancement by the readers when the lesions met the BI-RADS fifth edition definition of non-mass enhancement: abnormal enhancement larger than a focus without a space-occupying effect. 17 Thirty of 918 lesions (3%) were reclassified as masses (3-dimensional spaceoccupying lesion), and 9 of 918 (1%) were reclassified as foci (dot of enhancement <5 mm). 17 These lesions were excluded from analysis. Furthermore, the readers used the BI-RADS fifth edition lexicon to independently evaluate distribution and internal enhancement patterns of the 879 non-mass enhancement lesions. The modifiers for non-mass enhancement distribution were focal, linear, segmental, regional, multiple regions, and diffuse. The internal enhancement pattern was classified as homogeneous, heterogeneous, clumped, and clustered ring. 17 Suspicious non-mass enhancement features were based on prior literature to be most associated with malignancy. These descriptors included linear, segmental distribution, and clumped and clustered ring internal enhancement.
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Statistical Analysis
Logistic regression for correlated data was used to assess whether demographic factors or lesion characteristics, alone or in combination, were predictive of a targeted US examination being recommended, a US correlate being seen, or non-mass enhancement being malignant. Generalized estimating equations based on binary logistic regression were used to model each binary outcome as a function of demographic and lesion level factors. The time to biopsy and time to surgery were summarized in terms of medians and interquartile ranges, and mixed-model analysis of variance based on ranks was used to compare patients for whom a targeted US examination was and was not performed in terms of these variables. To account for the lack of statistical independence among results from patients with multiple lesions, the covariance structure for generalized estimating equations and analysis of variance was modeled by assuming results to be symmetrically correlated when acquired from the same patient and independent when derived for different patients. All statistical tests were conducted at the 2-sided 5% significance level with SAS version 9.3 software (SAS Institute, Cary, NC).
Results
The 879 retrospectively categorized non-mass enhancement lesions identified on breast MRI performed from January 2005 to December 2011 comprised the study sample. Figure 1 shows the management of the 879 lesions and pathologic results if biopsy was performed. Magnetic resonance imaging-directed US examinations were recommended in 331 cases (38%). A total of 284 (86%) had the recommended US examinations. Recommended US examinations were not performed in 47 of 331 lesions (14%) because of loss to follow-up in 28 of 47 (60%), subsequent surgery in 18 of 47 (38%), and direct performance of MRI-guided biopsy in 1 of 47 (2%), according to patient and referrer preference. The overall rate of US correlates for non-mass enhancement for those cases undergoing US assessment was 23% (64 of 284). Thirty-nine of these 64 (61%) underwent USguided biopsy, with an 18% (7 of 39) cancer yield. Of the remaining 25 of 64 US correlate cases (39%), in 5 of 25 cases (20%), surgical/oncologic management obviated biopsy because the patient underwent a mastectomy. The remaining 20 of 25 cases (80%) were benign and concordant. A 6-month follow-up US or MRI examination was not recommended for these 20 cases.
Overall Pathologic Outcomes of Non-Mass Enhancement for Biopsied Lesions
In total, 308 cases of non-mass enhancement were biopsied by either MRI-or US-guided biopsy. Our data show that both pure ductal carcinoma in situ (DCIS) and invasive cancers may manifest as non-mass enhancement (Table 1) . Non-mass enhancement was pure DCIS in 33 of 308 (11%) and invasive cancer in 22 of 308 (7%). Twelve of 22 invasive cancers (55%) were invasive ductal carcinoma, and 10 of 22 (45%) were invasive lobular carcinoma. Forty-nine of 308 biopsied non-mass enhancements (16%) yielded high-risk lesions or atypia on initial biopsy; none were upgraded on surgical excision. In our cohort, 202 of 308 (66%) were benign.
Predictors of US Correlates for Non-Mass Enhancement
We evaluated whether imaging features could be associated with the likelihood of a correlate on MRI-directed US imaging. We found no patient or lesion factors, 
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including mammographic density, background parenchymal enhancement, size, distribution, internal enhancement pattern, and enhancement kinetics, to be predictive of a correlate ( Table 2) .
Presence of a Landmark
We found that the presence of an adjacent landmark increased the likelihood of identifying a correlate. Example cases are shown in Figures 2-5 . Sixty-one landmarks with a mean size of 2.5 cm (range, 0.2-6.0 cm) were identified within 3 cm of the non-mass enhancement on MRI. The landmarks were index cancers, areas of postsurgical changes including a scar or seroma, biopsy sites or biopsy clips, benign masses, and dilated ducts ( Table  3 ). All landmarks seen on MRI were reproduced on US imaging. A US correlate was found in 28 of 61 non-mass enhancement lesions with an adjacent landmark (45.9%) compared to 36 of 223 non-mass enhancement lesions with no landmark (16.1%; P < .001; Table 2 ). When an index cancer served as the landmark, the malignancy rate for the US correlate was 4 of 12 (33%). Three of 4 of these correlates were invasive, and 1 was DCIS. When the landmark was not an index cancer, the malignancy rate for the US correlate was much lower: 2 of 49 (4%).
The identification of a landmark adjacent to the non-mass enhancement was helpful because the US correlate often did not measure precisely the same size as the non-mass enhancement lesion. In 16 of 28 cases (57%), the US correlate measured within 5 mm; 1 (6%) was malignant. Ten of 28 non-mass enhancement findings (36%) were 5 mm larger than their US correlates, and 5 (50%) of these were malignant. Two of 28 nonmass enhancement findings (7%) were 5 mm smaller than their US correlates; both were benign.
Predictors of Non-Mass Enhancement Being Malignant
For non-mass enhancement that was biopsied with either MRI or US guidance, patient demographics and lesion features were analyzed to determine predictors of non-mass enhancement being malignant ( Table 2) . Malignant non-mass enhancement was significantly more prevalent in the setting of a known index cancer (38 of 135 [28.2%]) than if no known cancer was present (17 of 173 [9.8%]; P < .001).
Age was also a significant predictor of malignancy (mean 6 SD, 47.4 6 11.4 years among patients without malignant non-mass enhancement versus 56.1 6 9.4 years among patients with malignant non-mass enhancement; P < .001). As a predictor of malignancy, age achieved an area under the curve of 0.73, sensitivity of 70.9% (39 of 55), and specificity of 63.2% (160 of 253) when lesions were classified as test-positive for malignancy for patients older than 50 years.
The presence of an adjacent landmark was predictive of malignancy, with malignant non-mass enhancement significantly more prevalent when a landmark was present (20 of 60 [33.3%]) than in the absence of a landmark (35 of 248 [14.1%]; P 5 .002).
The mean malignant lesion size was larger (25.9 6 20.3 mm) than the mean benign lesion size (20.7 6 12.6 mm; P 5 .019). No other imaging features, including mammographic density, background parenchymal enhancement, distribution, internal enhancement pattern, Data are presented as number (percent). a High-risk lesions were defined as atypia, including atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, papillary lesions, and complex sclerosing lesions. All high-risk lesions were confirmed on surgical excision; none were upgraded to malignancy.
and enhancement kinetics, were predictive of a non-mass enhancement lesion being malignant ( Table 2) .
Effect of Targeted US Examinations on the Time to Biopsy and Surgery
The elapsed time from the diagnostic MRI examination to biopsy was compared, as was the time from MRI to surgery. When an MRI-directed US examination was performed, the time to biopsy was significantly longer (P < .001) than when no MRI-directed US examination was performed (median, 14.0 versus 7.0 days; Table 4 ). However, there was no significant difference in the time to surgery between the groups (P 5 .445; median, 27.0 days when an MRI-directed US examination was performed versus 26.0 days when no MRI-directed US examination was performed).
Discussion
Diagnostic Yield of MRI-Directed US Imaging for Non-Mass Enhancement Most prior studies investigating MRI-directed US imaging have included all lesion types and have been limited by relatively small non-mass enhancement sample sizes ( Table 5) . 1, [3] [4] [5] 9, 10, 15, [23] [24] [25] These studies showed masses to be the lesion type most likely to have a US correlate. Compared to the reported rate of US correlates for masses of 49% to 92%, the yield for non-mass enhancement has been shown to be relatively low: 0% to 54%.
1,3-5,9,10,15,23-26 Our 23% US correlate rate for nonmass enhancement falls within this reported range. To our knowledge, our sample of 284 non-mass enhancement lesions is the largest single series reported to date Data are presented as median (range) and number (percent). P values were derived from a generalized estimating equation to assess whether demographic and lesion-level factors were predictive of a targeted US examination being recommended, a US correlate being seen, or non-mass enhancement being malignant. and approaches the 303 instances of non-mass enhancement included in a recent meta-analysis. 10 The pooled estimate of US correlates for non-mass enhancement in that meta-analysis was 29%.
In our study, the cancer yield for non-mass enhancement with a US correlate was 18% (7 of 39) versus 12% (14 of 117) for non-mass enhancement without a correlate. Although not statistically significant, our data follow a trend seen in other studies 15, 23 showing cancer more likely to have a correlate than a benign lesion. However, given the relatively high rate of lesions without a US correlate that ultimately yield malignancy: 12% in our study and 6% to 54% in other studies, [1] [2] [3] [4] [5] 14, 15, [23] [24] [25] [27] [28] [29] the absence of a correlate does not obviate biopsy of suspicious non-mass enhancement.
A Landmark Increases the MRI-Directed US Diagnostic Yield
Confident correlation on an MRI-directed US examination is challenging for many reasons. Common difficulties include differences in positioning and discrepancy in lesion size between MRI and US examination. A breast US examination is performed with the patient in the supine or supine oblique position with the arm raised, whereas breast MRI is performed with the patient prone. In the supine position with the arm raised, the breast tissue is flattened and widened, which makes the breast tissue, including breast lesions, appear more compact on US imaging than MRI. With MRI, the breast in the prone position is pendant, with little to no compression, which results in the tissue appearing more stretched in the anterior-to-posterior dimension, and lesions can appear more anterior on MRI than on US images. 30 Carbonaro et al 31 showed lesion displacement of about 3 to 6 cm along the 3 orthogonal directions on prone versus supine MRI, illustrating why identifying a correlate can be difficult. We found that a landmark within 3 cm of an MRI finding can serve as an effective internal reference and can lead to a substantially higher MRI-directed US yield. A correlate was seen for 45.9% of lesions when a landmark was present versus only 16.1% in the absence of a landmark. We have now modified our work flow such that we now always recommend US when a landmark is present. In instances with no landmark the decision for an MRI-directed US examination remains at the interpreting radiologist's discretion.
Similarly, a landmark may be particularly helpful in verifying a correlation when a size discrepancy is present. Levrini et al 32 demonstrated that malignant lesions may appear larger on MRI than US imaging. In our study, 36% of non-mass enhancement lesions with an adjacent landmark measured greater than 5 mm larger than their US counterparts. Fifty percent of biopsies in these cases of size discrepancies proved malignant. No prior literature specifically addressed possible size discrepancies when correlating MRI and MRI-directed US findings. However, others have proposed that MRI-detected malignancy may be subtle on US images; thus, the MRIdirected US examination should be meticulous to maximize the yield. 1 We hypothesize that non-mass enhancement with an adjacent landmark had a higher correlation rate because landmarks provided internal references that allowed for increased confidence of the correlation given discrepancies in size and conspicuity of US versus MRI findings. In our study, no other non-mass enhancement feature was predictive of a correlate. Meissnitzer et al 15 reported that an increasing non-mass enhancement lesion size, assessment of BI-RADS category 5 versus BI-RADS category 4, and clumped versus non-clumped enhancement increased the likelihood of identifying a US correlate. To our knowledge, no other study has demonstrated non-mass enhancement features that are predictive of a correlate.
Features of Suspicious Non-Mass Enhancement
In addition to the presence of an adjacent landmark, we found a larger lesion size to be significantly predictive of malignancy, with a mean lesion size of 26 mm for malignant non-mass enhancement versus 21 mm for benign non-mass enhancement. Our findings are in accordance with previous studies, including a study by Liberman et al, 33 which demonstrated a significantly increased positive predictive value (PPV) for malignancy in MRIdetected lesions with increasing lesion sizes. Specifically regarding non-mass enhancement, a recent study by Machida et al 34 demonstrated that non-mass enhancement of 1.0 cm or greater was more likely to be malignant. However, other authors did not find size to be predictive of malignancy for non-mass enhancement lesions. 35, 36 The level of suspicion for non-mass enhancement is based on its morphologic and internal enhancement features. Some investigators who have correlated the pathologic outcomes of the morphologic and internal enhancement characteristics of non-mass enhancement lesions found that the features of non-mass enhancement with the highest PPV of malignancy were linear (PPV, 0.167), 19 ductal (PPVs, 0.500 and 0.590), 19, 21 and segmental (PPVs, 0.100, 0.67, and 0.78) 18, 19, 21 distribution, clumped (PPVs, 0.304, 0.41, and 0.60), 18, 19, 21 reticular or dendritic (PPV, 0.286), 19 and clustered ring (PPVs, 1.00 and 0.67), 20, 22 and homogeneous (PPV, 0.67) 21 internal enhancement patterns. Although our study did not find any given non-mass enhancement distribution or internal enhancement pattern to be significantly predictive of malignancy, we also found the features that had the highest PPV for malignancy were linear (PPV, 0.203) and segmental (PPV, 0.281) distributions and a clumped internal enhancement pattern (PPV, 0.241). Variations in non-mass enhancement descriptor PPVs in the literature may be related to differences in study designs and patient populations, as well as variability in MRI interpretation. More experience using the latest BI-RADS lexicon may increase standardization among breast imagers. Future investigations would be helpful to further guide breast imagers' evaluation of whether a given non-mass enhancement lesion shows features sufficiently suspicious to warrant biopsy. Our data also show that invasive cancers, in addition to DCIS, may manifest as non-mass enhancement. Of all biopsied non-mass enhancements that yielded malignancy, 40% (22 of 55) were invasive, and 60% (33 of 55) were pure DCIS. We found most malignant nonmass enhancement to be DCIS, as did Wilhelm et al, 37 who reported 53% of malignant non-mass enhancement to be DCIS, 37 and Liberman et al, 18 who reported 90% of malignant non-mass enhancement to be DCIS (9 of 10). Baltzer et al 35 found 13% (2 of 15) malignant nonmass enhancement lesions to be DCIS, and Ballesio et al 38 found 21% (15 of 73) malignant non-mass enhancement lesions to be DCIS. Forty-five percent of invasive cancers in our study were invasive lobular carcinoma, in accordance with the potential of this entity to be occult on mammography and US imaging and the growing body of literature reporting that invasive lobular carcinoma may manifest as non-mass enhancement. [39] [40] [41] In patients with a known malignancy, non-mass enhancement was more likely to reflect additional areas of malignancy, compared to screening examinations in which non-mass enhancement was more likely to ultimately reflect benign conditions. This finding was consistent with examinations performed to establish the extent of disease that show additional sites of malignancy. 36, [42] [43] [44] Given that both index cancers and biopsy cavities were considered landmarks, it follows that adjacent non-mass enhancement was more likely to reflect additional malignancy. Finally, non-mass enhancement was more likely to be malignant in older women, with a mean age of 56 years in patients with non-mass enhancement that ultimately proved malignant compared to a mean age of 47 years in patients with non-mass enhancement that ultimately proved benign, which was probably related to decreased hormonal influences after menopause and a higher cancer incidence with increasing patient age. Therefore, non-mass enhancement in the setting of a known malignancy, within 3 cm of a landmark, and in older (postmenopausal) women should increase level of suspicion for malignancy.
Although the likelihood of a US correlate in our study population was low, a finding consistent with previous works (Table 5) , an MRI-directed US examination for non-mass enhancement can still be worthwhile because it allows for the possibility of US-guided biopsy, which is more widely available, better tolerated, less expensive, and faster than MRI-guided biopsy. The 2015 national Medicare reimbursement is $1046.38 for MRIguided biopsy (first lesion) compared with $662.25 for US-guided biopsy and $90.55 for a limited breast US examination. 45 These rates have implications for optimizing the allocation of limited health care resources. Specifically, although some facilities may have the resources to always proceed directly to MRI-guided biopsy for non-mass enhancement lesions, this situation is often not the case. Thus, US-guided biopsy, if possible, becomes a more economical means of tissue sampling.
Effect on the Clinical Timeline
A potential criticism of performing an MRI-directed US examination is that it may delay definitive therapy; however, our data showed that surgery was not delayed. Although MRI-directed US examinations did delay time to biopsy, there was no significant difference in the time to surgery, which is the more clinically relevant interval. Although, to our knowledge, no prior literature specifically addressed the effect of MRI-directed US on the time to surgery, some studies have demonstrated an increased wait time when preoperative breast MRI is performed, 46 whereas others have demonstrated no delay. 47 Limitations Limitations of our study include its retrospective nature and the fact that it was performed at a single institution; results may not be transferrable to other settings. Additionally, US imaging is an operator-dependent modality. Ultrasound findings could not confidently be retrospectively reclassified, as were the MRI examinations. There was also a potential selection bias in that MRI-directed US examinations were recommended at the discretion of the interpreting radiologist; the correlation rate would likely have been different if all non-mass enhancements underwent MRI-directed US examinations. Subsequent imaging-pathologic correlation of the interpreting radiologist could therefore in turn have been affected. Finally, not all non-mass enhancement lesions went on to have MRI-directed US examinations even when recommended, for reasons including loss to follow-up, subsequent surgery, and direct procession to MRI-guided biopsy. Although this factor may have been a weakness of our study, our overall rate of 86% (284 of 331) of recommended MRI-directed US examinations that were performed for non-mass enhancement is within the range reported in the published literature on this topic: 74% to 90%. 4, 23, 25 Conclusions In our single-center retrospective study, suspicious nonmass enhancement that was identified adjacent to a landmark was more likely to have a US correlate. This finding could be generalizable to clinical settings in which a landmark, if present, may be used as an internal reference to guide US examinations and increase the likelihood of confidently identifying a correlate for biopsy. In such cases, a more confident correlation between MRI and US imaging could allow for US-guided biopsy, which is more widely available, better tolerated, less expensive, and faster than MRI-guided biopsy.
There was no statistical difference in the rate of malignancy between non-mass enhancement with or without a US correlate; therefore, the absence of a correlate does not obviate the need for biopsy of suspicious non-mass enhancement. However, we found that nonmass enhancement was more likely to be malignant when identified in the setting of a known index cancer, older patient age, a landmark, and a larger lesion size. Using this knowledge may help breast imagers optimize work flow and counsel patients regarding biopsy of suspicious non-mass enhancement.
